Eventide Healthcare & Life Sciences is not a bad option within its narrow niche, though most investors should approach it with caution due to its inherent volatility. It maintains its pillar scores of Above Average for People and Average for Process.
Eventide Healthcare & Life Sciences N ETNHX
- NAV / 1-Day Return 33.79 / −2.51 %
- Total Assets 1.5 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.510%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Small Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 79%
USD | NAV as of May 10, 2024 | 1-Day Return as of May 10, 2024, 10:12 PM GMT+0
Morningstar’s Analysis ETNHX
Will ETNHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 32.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Zentalis Pharmaceuticals Inc Ordinary Shares | 5.98 | 99.7 Mil | Healthcare |
Celldex Therapeutics Inc | 4.31 | 71.9 Mil | Healthcare |
Karuna Therapeutics Inc | 3.61 | 60.1 Mil | Healthcare |
Us Bank Mmda - Usbgfs 9 | 3.11 | 51.8 Mil | Cash and Equivalents |
Aura Biosciences Inc | 3.08 | 51.4 Mil | Healthcare |
Marinus Pharmaceuticals Inc | 2.95 | 49.2 Mil | Healthcare |
Cytokinetics Inc | 2.78 | 46.4 Mil | Healthcare |
Evolent Health Inc Class A | 2.57 | 42.9 Mil | Healthcare |
Exact Sciences Corp | 2.51 | 41.8 Mil | Healthcare |
Lexeo Therapeutics Inc | 2.42 | 40.3 Mil | Healthcare |